- NeoGenomics (NEO, Financial) launches PanTracer™ genomic profiling tests and Paletrra™ spatial proteomics platform at ASCO 2025.
- The new offerings aim to enhance precision oncology and support faster, informed treatment decisions.
- NeoGenomics will present these innovations through interactive experiences and scientific presentations at the event.
NeoGenomics, Inc. (NEO), a leader in oncology diagnostic solutions, is set to unveil its latest innovations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. From May 30 to June 3, 2025, the company will showcase its PanTracer™ Family of genomic profiling tests alongside the Paletrra™, an AI-driven spatial proteomics platform.
The PanTracer™ tests are designed to offer comprehensive genomic insights for oncologists, aiding treatment decisions for patients with advanced-stage solid tumors. This suite includes PanTracer™ Tissue, PanTracer™ LBx for liquid biopsies, and PanTracer™ Tissue + HRD for homologous recombination deficiency testing. These tests provide flexible options for genomic analysis depending on available tissue samples.
Paletrra™ represents a breakthrough in spatial proteomics, providing high-plex, image-based insights from tissue samples. This platform is tailored for translational research, allowing biopharma and biotech companies to make informed therapeutic decisions by decoding the tumor microenvironment with precision.
NeoGenomics will also engage attendees with an interactive experience, "Hey Neo," to demonstrate how PanTracer supports therapy selection in real-world scenarios. Additionally, the company will present a scientific poster and two abstracts online, highlighting their research contributions to oncology drug development and clinical trials.
